Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles

American Journal of Gastroenterology

Volumn 105, Issue 7, 2010, Pages 1661-1669

  Huang, Hai ^a   Dong, Xin ^a   Kang, Mu Xing ^a   Xu, Bin ^a   Chen, Ying ^a   Zhang, Bo ^a   Chen, Jian ^a   Xie, Qiu Ping ^a   Wu, Yu Lian ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ARG1 PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD177 PROTEIN; CYCLIC AMP; FLJ22662 PROTEIN; GELATINASE B; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LTF PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PGK1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VANIN 1;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; DIABETES MELLITUS; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATIC CANCER ASSOCIATED DIABETES; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VALIDATION STUDY;

ADULT; AGED; AMIDOHYDROLASES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77954426636     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.32     Document Type: Article

References (44)

1. Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer:basic and clinical aspects. Gastroenterology 2005; 128:1606-1625
2. Li D, Xie K, Wolf R, et al. Pancreatic cancer. Lancet 2004; 363:1049-1057
3. Yeo C J, Cameron JL, Sohn T A, et al. Six h u n d red f f y consecutive pancreaticoduodenectomies in the 1990s:pathology, complications, and outcomes. Ann Surg 1997; 226:248-57; discussion 57-60.
4. Nitecki S S, Sarr M G, Colby T V, et al. Long-term survival af er resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59-66.
5. Egawa S, Takeda K, Fukuyama S et al. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004;28:235-240
6. Shimizu Y, Yasui K, Matsueda K et al. Small carcinoma of the pancreas is curable: new computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol 2005;20:1591-1594
7. Shimada K, Sakamoto Y, Sano T et al. Reappraisal of the clinical signifcance of tumor size in patients with pancreatic ductal carcinoma. Pancreas 2006;33:233-239
8. Ishikawa O, Ohigashi H, Imaoka S et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter \- collective review of Japanese case reports. Hepatogastroenterology 1999;46:8-15.
9. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134:95-101.
10. Chari ST, Leibson C L, Ra be KG et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129: 504-511
11. Ogawa Y, Tanaka M, Inoue K et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002;94:2344-2349
12. Pannala R, Basu A, Petersen GM et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
13. Shanlian LG-e H, Zhang-rong X, Da-Kui L et al. Current status of epidemic and economic burden of diabetes mellitus in China. Chinese Health Econ 2008;27:5-8.
14. American Diabetes Association. Diagnosis and classifcation of diabetes mellitus. Diabetes Care 2007;30 (Suppl 1): S42-7.
15. Eisen MB, Spellman PT, Brown PO et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-14868
16. Pitari G, Malergue F, Martin F et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 defcient mice. FEBS Lett 2000;483:149-154
17. Cwik G, Wallner G, Skoczylas T et al. Cancer antigens 19-29 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006;141:968-73; discussion 18.
18. Boeck S, Stieber P, Holdenrieder S et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255-264
19. Saf F, Schlosser W, Kolb G et al. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106-112
20. Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 1997;6:157-169
21. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186
22. Satake K, Takeuchi T, Homma T et al. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994; 9: 703-706
23. Oto A, Eltorky M A, Dave A et al. Mimicks of pancreatic malignancy in patients with chronic pancreatitis: correlation of computed tomography imaging features with histopathologic fndings. Curr Probl Diagn Radiol 2006;35:199-205.
24. Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc 2002;55:232-237
25. Barthet M, Portal I, Boujaoude J et al. Endoscopic ultrasonographic diagnosis of pancreatic cancer complicating chronic pancreatitis. Endoscopy 1996; 28: 487-491
26. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160: 1239-1249
27. Karanjawala ZE, Illei PB, Ashfaq R et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008;32:188-196
28. Segara D, Biankin AV, Kench J G et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res 2005; 11: 3587-3596
29. Logsdon CD, Simeone DM, Binkley C et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifes multiple genes diferentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-2657
30. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
31. Han M, Liew CT, Zhang H W et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008; 14: 455-460
32. Osman I, Bajorin DF, Sun TT et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res 2006;12:3374-3380
33. Burczynski ME, Twine NC, Dukart G et al. Tran scriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 2005; 11: 1181-1189
34. Pelaez-Luna M, Takahashi N, Fletcher JG et al. Resectability of presymp-tomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007;102:2157-2163
35. Maras B, Barra D, Dupre S et al. Is pantetheinase the actual identity of mouse and human vanin-1 proteins? FEBS Lett 1999; 461: 149-152
36. Dupre S, Graziani MT, Rosei MA et al. The enzymatic breakdown of pantethine to pantothenic acid and cystamine. Eur J Biochem 1970; 16: 571-578
37. Berruyer C, Martin FM, Castellano R et al. Vanin-1#sup#- /-#/sup# mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol 2004;24:7214-7224
38. Martin F, Penet MF, Malergue F et al. Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inf ammation associated with higher glutathione stores. J Clin Invest 2004;113:591-597
39. Roisin-Boufa y C, Castellano R, Valero R et al. Mouse vanin-1 is cytopro-tective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia 2008; 51: 1192-1201
40. Collins HM, Morris T M, Watson SA. Spectrum of matrix metallo protein ase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001;84:1664-1670
41. Kapischke M, Fischer T, Tiessen K et al. Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in v itro and in an or thotopic pancreatic cancer model in v ivo. Int J Oncol 2008; 32: 273-282
42. Hurst NG, Stocken D D, Wilson S et al. Elevated serum matrix metal-loproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007; 97: 971-977
43. Somiari SB, Somiari RI, Heckman C M et al. Circulating MMP2 and MMP9 in breast cancer \- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006;119:1403-1411
44. Wilson S, Taskila T, Ismail T et al. Establishing the added benef t of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme. BMC Cancer 2009; 9